Drug Profile


Alternative Names: HAL-MEP1; Peanut allergy immunotherapy - HAL Allergy; Peanut allergy vaccine - HAL Allergy; Peanut extract - HAL Allergy

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HAL Allergy
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Peanut hypersensitivity

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Peanut-hypersensitivity in Netherlands (SC)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Peanut-hypersensitivity in Denmark (SC)
  • 03 Mar 2017 Safety data from a phase I trial in Peanut hypersensitivity presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top